0.00Open0.00Pre Close0 Volume0 Open Interest25.50Strike Price0.00Turnover0.00%IV44.92%PremiumMay 2, 2025Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma926.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
SpringWorks Therapeutics Stock Discussion
Acquisition brings two FDA-approved rare tumor therapies to Merck KGaA's portfolio, creating leadership position in high-unmet-need markets.
This acquisition strategically enhances Merck KGaA's position in specialized rare tumor markets by adding two recently FDA-approved therapies with distinctive market positions. SpringWorks contributes OGSIVEO® (nirogacestat), a first-in-class therapy established as the systemic standard-of...
Merck KGaA's $3.9B acquisition of SpringWorks offers 26% premium to shareholders while strategically expanding Merck's rare tumor portfolio.
The $47 per share all-cash acquisition of SpringWorks by Merck KGaA represents a 26% premium to SpringWorks' unaffected 20-day volume-weighted average price before market speculation. This translates to an equity value of approximately $3.9 billion and enterprise value of $3.4 billion (€3.0 billion), pr...
Merck KGaA's $3.9B SpringWorks Acquisition Brings Revolutionary Rare Disease Treatments Under Its Wing
EU Regulators Set to Rule on SpringWorks' Breakthrough Desmoid Tumor Treatment in Q2 2025
Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion - reuters.com/bus...
Exclusive: US pharma tariffs would raise US drug costs by $51 billion annually, report finds - reuters.com/bus...
It might cost cheaper to produce medicine 💊 oversea
WSJ· 5 mins ago
WSJ· 5 mins ago
No comment yet